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Abstract: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central   nervous 
system (CNS) that represents one of the first causes of neurological disability in young 
adults. Although the pathogenesis of MS is still unclear, an autoimmune mechanism has been 
  demonstrated. According to this evidence in the last 15 years different treatments acting on 
the immune system have been developed. Current disease-modifying drugs (DMDs) for MS 
require regular and frequent parenteral administration and are associated with limited   long-term 
  treatment adherence. Moreover the clinical efficacy of these disease-modifying drugs is 
  suboptimal. Thus, there is an important need for the development of new therapeutic strategies. 
Several oral   therapies (fingolimod, fumaric acid, teriflunomide, laquinimod) are in development; 
Among these cladribine is the only therapy with the potential for short-course dosing. Cladrib-
ine is an immunosuppressant that offers sustained regulation of the immune system through a 
preferential lymphocyte depleting action. Cladribine has a well-characterized and well-known 
safety profile, derived from more than 15 years of use of the parenteral formulation both in the 
oncology field and in MS. This paper reviews the new oral emerging treatments and presents the 
available data about the use of cladribine in MS and the future perspective of its clinical use.
Keywords: multiple sclerosis, disease modifying drugs, oral therapy, treatment adherence, 
cladribine
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS) that can lead to severe disability in many young adult patients, and is one of the most 
common causes of neurological disability in this population.1 In this inflammatory and neu-
rodegenerative disorder, autoreactive immune cells, cytokines, macrophages, and antibodies 
attack myelin sheaths and injure underlying axons. The accumulation of axonal damage 
leads to permanent loss of neurological function.2 The disease course varies among 
patients: most patients present initially with relapsing-remitting (RR) MS, in which partial 
or complete recovery from neurological function occurs during periods of remission.3 
However a large proportion of patients (approximately half) subsequently develop sec-
ondary progressive (SP) MS, in which disability continues to accumulate irrespective of 
relapse activity and few effective therapies could be used apart from symptomatic ones.4 
Early recognition and treatment of MS to reduce the risk and to   mitigate the severity of 
relapses has the potential to forestall the accrual of disability.5
The past 15 years have witnessed the introduction of several therapies for MS. Treat-
ment of RRMS typically consists of direct symptom management, brief corticosteroid 
administration for acute exacerbations, and the regular use of disease modifying Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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drugs (DMDs). Currently approved immumomodulator 
treatments for RRMS include glatiramer acetate (GA) and 
recombinant interferons (IFNβ) (IFNβ-1a Avonex®, IFNβ-1a 
Rebif®, IFNβ-1b Betaseron®,   Extavia®) that represent the 
gold standard in modifying the course of MS. Natalizumab 
(Tysabri®) and mitoxantrone (Novantrone®) are also available 
for treatment of MS as second line therapy. Nevertheless, in 
clinical practice DMDs or immunosuppressive treatments 
are frequently associated with suboptimal response in terms 
of efficacy. It has been demonstrated that a proportion of 
patients treated with   interferons develop neutralizing antibod-
ies during their therapy, although this only partially explains 
the suboptimal response to IFNβ   treatment.6 Patients treated 
with interferons often experience several side effects such 
as flu-like   symptoms and   injections side reactions that can 
frequently lead to poor patient adherence. These DMDs for 
MS require long term, regular injection or monthly parenteral 
infusions, which may be uncomfortable and inconvenient 
for the patient. This may affect adherence and could easily 
lead to patients dropping out of therapy.7 Thus there is an 
important need for new therapeutic strategies, especially 
those that may offer greater patient satisfaction in order to 
optimize therapeutic outcomes. Currently there are more than 
30 compounds which have already been tested or are await-
ing Phase II studies in MS.8 Phase III studies with cladribine 
tablets have been completed, and following marketing autho-
rization application cladribine could become the first orally 
administered DMD for patients with RRMS. Here, we review 
oral compounds that have successfully completed their first 
clinical trials, focusing on cladribine tablets and its expected 
impact on clinical practice.
Oral MS therapies in development
A number of potential therapies for MS are now in   late-stage 
development. To improve patient compliance with   treatment 
and reduce lack of adherence, most of these are oral 
  compounds and include: fingolimod (FTY720), fumaric 
acid (BG12), teriflunomide (A77126 or HMR1726) and 
laquinimod (ABR-215062).
Fingolimod is a structural analogue of sphingosine that 
interferes with cell traffic between organs and blood. In a 
6-month placebo controlled Phase II study in 281 patients with 
RRMS oral fingolimod at doses of 1.25 and 5 mg   significantly 
reduced inflammatory disease activity as measured by 
  magnetic resonance imaging (MRI) (up to 80%, P , 0.001 
for the higher dose) and clinical relapse rate by more than 
50% (6-month annualized relapse rate of 0.35–0.36 with fin-
golimod for the two doses vs 0.77 with placebo; P # 0.01 for 
both doses).9 Common side effects included dose-dependent 
transient arrhythmias within hours of the first dose, increased 
mean arterial blood pressure, and airway obstruction.
Patients who received the higher dose of fingolimod 
(5 mg) had more frequent upper respiratory tract infections 
than patients who received the lower dose (1.25 mg) or 
placebo. In view of the frequency and severity of the side 
effects observed in the high-dose group (5 mg), a Phase III 
study assessing the efficacy of the 1.25 mg dose and a lower 
dose of 0.5 mg has been developed in RRMS patients. The 
FTY720 Research Evaluating Effects of Daily Oral Therapy 
in Multiple Sclerosis (FREEDOMS) study demonstrated that 
the aggregate annualized relapse rate (the primary endpoint) 
was lower with fingolimod at a dose of 0.5 mg (0.18) and 
with fingolimod at a dose of 1.25 mg (0.16) than with placebo 
(0.40), representing relative reductions of 54% and 60%, 
respectively, in the annualized relapse rate (P , 0.001). The 
time to disability progression, with confirmation either after 
3 months (the key secondary end point) or after 6 months, 
was longer with both fingolimod doses than with placebo, as 
also were MRI-related end points expressed as the number 
of gadolinium (Gd)-enhancing lesions at 24 months and 
an absence of Gd-enhancing lesions at 24 months – both 
P , 0.001.10
Moreover a 12-month, double-blind, double-dummy study 
in which 1292 patients with relapsing-remitting multiple 
sclerosis who had a recent history of at least one relapse 
were randomly assigned to receive either oral fingolimod at a 
daily dose of either 1.25 or 0.5 mg or intramuscular IFNβ-1a 
(Avonex®) at a weekly dose of 30 µg to evaluate the compari-
son in terms of relapse rate and MRI outcomes eg, new or 
enlarged lesions on T2-weighted images, or gadolinium (Gd)-
enhancing lesions on T1-weighted images. MRI measurement 
used to compare the two drugs showed a consistent result of 
the superior efficacy of oral fingolimod.11
Fumaric acid (FA) is an unsaturated dicarboxylic acid, 
isomeric to maleic acid, which acts as an intermediate in the 
Krebs cycle. Its exact mechanism of action is still unclear, but 
it appears to induce depletion of peripheral blood leukocytes 
owing mainly to a reduction in the number of T cells. In vitro 
studies indicate that fumaric acid esters (FAEs) induce a shift 
from Th1 to Th2 cytokines as part of their treatment effect.12 
In an open label prospective study involving 10 patients with 
RRMS, FA produced significant reductions from baseline in the 
number (P , 0.05) and volume (P , 0.01) of Gd-enhancing 
lesions after 18 weeks of treatment at a target dose of 720 
mg/day; this effect persisted through the second 48-week 
treatment phase at half the target dose, following a 4-week Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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washout period.13 In a 24-week, double-blind, randomized, 
placebo-controlled Phase IIb study in RRMS patients (n = 257), 
MRI analysis revealed a significant and   dose-dependent reduc-
tion of brain lesion activity, particularly after treatment with 
the 720-mg dosage. In comparison to placebo, this group 
demonstrated ∼70% reduction in Gd-enhancing lesions and 
a 50% reduction in new or enlarging T2 lesions and new T1 
hypointense lesions.14 The most commonly observed adverse 
events (AE)s were flushing, nasopharyngitis, headache, nausea, 
diarrhea, fatigue, pruritus, upper abdominal pain, and hot flush, 
with evidence of a dose-related influence on the frequency of 
most of these AEs.
Teriflunomide is the active metabolite of leflunomide. 
Leflunomide blocks de novo pyrimidine synthesis by 
  inhibiting dihydro-orotate dehydrogenase in T-cell and 
other rapidly dividing cell populations, leading to a 
decrease in DNA synthesis.15 Leflunomide is licensed for 
the treatment of rheumatoid arthritis and is also effective 
in experimental autoimmune neuritis and rat experimental 
autoimmune encephalomyelitis (EAE).16–17 A recent 
randomized, double-blind, placebo-controlled, parallel-
group trial assessed the safety and efficacy of this new drug 
on MS: 179 patients (157 with RRMS, 29 with SPMS) have 
been treated with placebo (n = 61), teriflunomide 7 mg/day 
(n = 61), or teriflunomide 14 mg/day (n = 57) for 36 weeks. 
Treatment with teriflunomide 7 or 14 mg/day resulted in the 
significant suppression of . 61% of MRI activity relative to 
placebo (P , 0.03 at the dosage of 7 mg/day and P , 0.001 
at the dosage of 14 mg/day). The annualized relapse rate 
between placebo and teriflunomide 14 mg/day was similar 
to that reported for IFNβ and GA (32%). The higher dose of 
teriflunomide (14 mg/day) appears to be more effective than 
the 7 mg/day dose, in terms of relapse rate, although no dose 
effect was observed on primary endpoints such as Gd-enhanc-
ing lesions and new/enlarging T2 lesions.18 AEs reported more 
frequently in the treatment groups than in the placebo group 
were: neutropenia, nasopharyngitis, alopecia, nausea, increase 
in alanine aminotransferase, paresthesia, back and limb pain, 
diarrhea and arthralgia. Combination studies of teriflunomide 
with IFNβ or GA and a trial investigating teriflunomide in 
clinically isolated syndrome are underway.
Laquinimod is a novel synthetic compound with oral 
  bioavailability, that is in development as an oral   formulation 
for the treatment of MS. Laquinimod was effective in a 
rat model of EAE, in which its efficacy was ascribed to 
  modulation of the balance of the T-helper (Th) cells 1 and 
2 induction of transforming growth factor β.19 However, the 
exact mechanism of action in MS patients is still   ambiguous. 
The efficacy of laquinimod was studied in two phase II 
  studies.20 The first phase II clinical trials showed i  nconclusive 
results on the effect of a 0.3 mg dose and led to further 
exploration of the therapeutic dose in an additional phase 
IIb study. The second study was a phase IIb, multinational, 
randomized, double-blind, parallel-group, placebo-controlled 
36-week study, evaluating the efficacy, tolerability and safety 
of two daily oral doses (0.3 and 0.6 mg) of laquinimod 
(as compared to placebo) in subjects with RRMS. A total 
of 306 patients were randomized, with 98 subjects assigned 
to laquinimod 0.3 mg, 106 to laquinimod 0.6 mg, and 102 
to placebo. The statistical analysis on the intention-to-treat 
(ITT) population for the primary endpoint demonstrated 
a statistically-significant treatment effect of laquinimod 
0.6 mg compared to placebo (P = 0.0048), with a reduction 
of 40% in the cumulative number of Gd-enhancing lesions 
at weeks 24, 28, 32 and 36. A nonsignificant treatment effect 
of 8% was observed with laquinimod 0.3 mg (P = 0.6740). 
A statistically-significant reduction of treatment effect of 
laquinimod 0.6 compared to placebo was demonstrated 
for other MRI-related endpoints, defined in the protocol 
as secondary endpoints.20 Based on a thorough review of 
all laquinimod clinical data available to date, the primary 
safety concerns include potential hepatotoxicity and a pos-
sible proinflammatory effect. Four serious adverse event AEs 
(SAEs) were reported: pleuritis, Budd–Chiari syndrome, 
pituitary adenoma with hemorrhage and a possible diagnosis 
of Crohn’s disease. Pharyngolaryngeal pain, dyspepsia and 
ankle edema were also observed. Laboratory abnormalities 
seen in Phase II laquinimod studies include elevated white 
blood count, elevated fibrinogen levels, a trend towards 
decreased hemoglobin, elevated liver enzymes and increased 
of amylase.
Introduction to cladribine
Cladribine (2-chloro-2′-deoxyadenosine [2-CdA]) is an 
adenosine deaminase-resistant purine nucleoside analogue 
that preferentially reduces lymphocyte subpopulations. The 
molecule was first investigated at the Scripps Research 
Institute (CA, USA) in the late 1970s for the treatment of 
lymphoid malignancies. Carson and colleagues discovered 
that a deficiency of adenosine deaminase led to accumulation 
of intracellular toxic deoxyadenosine nucleosides and their 
phosphorylated products within lymphocytes, and resulted in 
selective lymphopenia.21 Based on these results, synthesis of 
several purine analogues began, among which cladribine was 
the most potent, offering targeted, sustained regulation of the 
immune system. The cladribine prodrug enters cells via purine Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
394
Gasperini et al
nucleoside transporters and once within the cell, undergoes 
initial phosphorylation by deoxycytidine kinase.22 Lympho-
cytes are particularly susceptible to the effects of cladribine 
because of their high intracellular ratio of   deoxycytidine kinase 
to 5’-nucleotidase. The accumulation of cladribine nucleotides 
disrupts DNA synthesis and repair, and ultimately leads to 
sustained reduction in lymphocytes. Cladribine is able to cross 
the blood–brain barrier (BBB)22 and is, therefore, likely to act 
on cells in both the periphery and CNS appearing to have a 
greater effect on CD4+ T cells than the CD8+ T cell popula-
tion.23 The parenteral formulation of cladribine has been used 
extensively for the reduction of aberrant lymphocyte popula-
tions in the hematological oncology setting. It is indicated for 
the treatment of hairy cell leukemia (HCL), and has been used 
in the treatment of several other leukemias and lymphomas.24 
The sustained effects of cladribine treatment support the use 
of an annual, short-course dosing regimen. Furthermore, 
a preservation of cell types that are key to maintenance of 
innate immune function has been observed, which may explain 
the low number of infections that occurred following cladrib-
ine treatment despite a reduction in lymphocyte numbers. 
Since MS is known to be an autoimmune disease, parenteral 
cladribine was evaluated in Phase II/III clinical trials in patients 
with RRMS or progressive MS.23–25 Cladribine tablets were 
  consequently developed.
Clinical efficacy and safety profile  
of cladribine in MS
Clinical trials
Parenteral cladribine has been investigated for treatment effi-
cacy in different autoimmune disorders, including MS, such 
as rheumatoid arthritis and systemic lupus erythematosus-
associated glomerulonephritis.26 Current knowledge on the 
efficacy and safety of cladribine tablets in MS is based on 
data from the CLARITY study. This is supported by histori-
cal studies which evaluated parenteral cladribine in relapsing 
and progressive forms of MS. The key findings from these 
studies are summarized below (Table 1).
Three randomized, double-blind, parallel-group, placebo-
controlled, phase II/III trials conducted at the Scripps Research 
Institute (Scripps-C, MS-Scripps and MS-001) have been 
performed in patients with MS to assess the efficacy and safety 
of cladribine.23–25 In the placebo-controlled phases of these 
studies, 183 patients received intravenous or subcutaneous 
cladribine, at doses of 0.7–2.8 mg/kg, administered in monthly 
5- to 7-day courses for 2–6 months, and were followed for up 
to 24 months. These studies showed statistically-significant 
improvement in MRI measures of activity (Table 1). In the 
18-month (Scripps-C) study, 52 patients with RRMS received 
cladribine, 2.1 mg/kg subcutaneously (SC), or placebo, over 
6 months, and were followed for a further 12 months. The 
primary endpoints of the study were the frequency and sever-
ity of the relapses and the number of Gd-enhancing lesions 
observed at MRI scan. A significant reduction in frequency 
and severity of relapses was observed in patients receiving 
cladribine compared with those receiving placebo from 
months 7–12 (P = 0.021), which was maintained at month 
18 (P = 0.010). There was also a significant reduction in the 
occurrence of Gd-enhancing lesions at 12 months compared 
with placebo (P = 0.0001), which remained significant lower 
at 18 months (P = 0.002).27 Patients with primary or second-
ary progressive forms of MS, received parenteral cladribine 
in the 12-month MS-001 and 24-month treatment crossover 
MS-Scripps studies.25 In the MS-001 study cladribine led to 
a .90% reduction in the mean number of T1 Gd-enhancing 
lesions at 6 months which was maintained throughout the 
study (P # 0.005 for the 0.7 mg/kg group and P = 0.001 
for the 2.1 mg/kg group, versus placebo at final evaluation) 
and a .90% reduction in mean volume of T1 Gd-enhancing 
lesions in both cladribine groups after 6 months, which 
was also maintained throughout the study (P , 0.001 after 
18 months and P = 0.007 after 24 months vs placebo). No 
significant differences in primary clinical outcomes (mean 
change in Expanded Disability Status Scale [EDSS] score) 
were detected between patients in the cladribine groups and 
placebo, but a trend toward a later time to disability progres-
sion was found in cladribine-treated patients compared to 
placebo in the SPMS subgroup. The lack of effect of cladribine 
on the disability measures in contrast to its dramatic impact on 
MRI measures has been explained by the short duration of 
the trial and by the high baseline EDSS score (median 6.0) 
of the study population.25 Prior to treatment crossover in 
the MS-Scripps study (after 12 months), significantly fewer 
patients receiving   cladribine (2.8 mg/kg) than placebo had 
Gd-enhancing lesions (P , 0.001). Furthermore there was an 
improvement in mean EDSS and Scripps Neurological Rating 
Scale (SNRS) scores (P , 0.01 and P , 0.001, vs placebo, 
respectively). However it must be considered that both 
  primary and secondary progressive patients were included, 
so those results might be difficult to interpret.
Building on the experience with parenteral administra-
tion, short-course therapy with cladribine tablets was inves-
tigated for RRMS in the CLARITY study (CLAdRIbine 
Tablets treating multiple sclerosis orallY).28 CLARITY was 
a Phase III, randomized, double-blind, placebo-controlled, 
multicentre, 96-week study with three parallel groups to Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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assess the efficacy of cladribine tablets in patients aged 18–65 
years with a diagnosis of RRMS according to the McDonald 
criteria. The primary endpoint of the study was to evaluate the 
efficacy of cladribine tablets versus placebo in reducing the 
relapse rate during 96 weeks of treatment. The dosing regi-
men for the cladribine tablets consisted of two or four short 
courses per year (cumulative dose of 3.5 and 5.35 mg/kg over 
the 96-week study, respectively). Treatment with 3.5 and 5.25 
mg/kg cladribine tablets significantly reduced the annualized 
relapse rate to Week 96 (relative reduction 57.6% and 54.5% 
vs placebo, respectively, both P , 0.001) and resulted in 
significantly more relapse-free patients at Week 96 (79.7% 
and 78.9% vs 60.9%, respectively; odds ratios: 2.53 and 2.43, 
both P , 0.001).28 Three measures were detected: T1 gad-
olinium-enhancing lesions, active T2 lesions and combined 
unique lesions (all P , 0.001 vs placebo). The results from 
CLARITY demonstrated that annual short-course dosing 
with cladribine tablets at both dosing regimens (3.5 mg/kg 
and 5.25 mg/kg) provided rapid and sustained improvements 
in clinical and MRI outcomes for patients with RRMS over 
the duration of the 96-week study (Table 2).
Safety and tolerability
The safety of cladribine has been well-known on the basis of 
wide experience acquired during years of study across differ-
ent medical fields. Cladribine was generally well-tolerated in 
the individual Scripps studies in MS.29,30 In a pooled analysis 
of the data with cladribine vs placebo from the three Scripps 
studies and an additional supportive study in patients with 
MS, the most commonly reported treatment-emergent AEs 
were upper respiratory tract infections (32 vs 24%), head-
aches (28 vs 38%) and injection-site reactions (24 vs 25%).27 
There was a small dose-related increase in the frequency of 
upper respiratory tract and urinary tract infections (UTIs). 
AEs reported more often with cladribine than placebo 
treatment were hypertonia; purpura, muscle weakness and 
upper respiratory tract infections.29 No serious adverse 
events (SAEs) related to cardiotoxicity, nephrotoxicity or 
neurotoxicity were reported in the Scripps studies, consistent 
with the observation in oncology patients. As expected from 
its mechanism of action, cladribine treatment significantly 
reduced the number of leukocytes in these studies. However 
the incidence of infections remained low, mainly comprising 
Table 1 Efficacy data from Phase II/III scripps studies of parenteral cladribine for MS23,24,35
Study Dose regimen 
(total dose)
MRI Gd+ lesions Neurologic outcomes
Scripps-C 0.07 mg/kg/day SC 5 days/month  
for 6 months (2.1 mg/kg)
Reduced number of 
lesions at 6 and 12 months  
relative to baseline (P , 0.003 
vs placebo)
Reduced frequency 
and severity of 
relapses vs placebo (P = 
0.021)
MS-Scripps  Year 1: 0.1 mg/kg/day IV 7 days  
for 4 months (2.8 mg/kg); 
Year 2: 0.1 mg/kg/day IV 7 days  
for 1 month and 0.05 mg/kg/day 
IV 7 days for 2 months (1.4 mg/kg)
Reduced proportion of 
patients with lesions at 
12 months compared 
with placebo (P , 0.001)
improvement in mean 
eDSS and SNRS 
scores (P , 0.01 and 
P , 0.001 vs 
placebo, respectively)
MS-001 0.07 mg/kg/day SC 
5 days/month for  
6 months (2.1 mg/kg); 
0.07 mg/kg/day SC 
5 days/month for  
2 months (0.7 mg/kg)
$90% reduction in the 
mean number of lesions 
at 6 months and 
maintained throughout 
the study; 
(P # 0.005 for 0.7 mg/kg 
group and P = 0.001 for 
2.1 mg/kg group vs 
placebo at final 
evaluation) 
.90% reduction in 
mean volume of lesions 
in both cladribine groups 
after 6 months and 
maintained throughout 
the study (P , 0.001 
after 18 months and  
P = 0.007 after 24 months 
vs placebo)
No significant 
differences in primary 
clinical outcomes 
(EDSS) between the 
two groups; a trend 
toward a later time to 
disability progression 
was found in 
cladribine-treated 
patients vs placebo in 
the SPMS subgroup
Abbreviations: eDSS, expanded disability status scale; Gd+, gadolinium-enhancing; iv, intravenous; SC, subcutaneous; SNRS, scripps neurologic ratings scale.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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UTIs and herpes zoster reactivation, and overall was similar 
between patients treated with cladribine or placebo.30 Paren-
teral cladribine has been shown to be teratogenic in mice and 
rabbits, but its effects on human fertility and development are 
not known. Parental cladribine is not recommended for use 
by pregnant women, and adequate contraceptive precautions 
should be taken by patients of child-bearing age receiving 
cladribine treatment.
The safety profile of cladribine tablets in the CLAR-
ITY study, was as expected from the Scripps studies and 
its mechanism of action. Lymphopenia occurred more 
frequently in patients treated with cladribine tablets at 
both dosages than with placebo (21.6%, 31.5% vs 1.8% 
patients, respectively).28 Despite the lymphopenia observed 
in cladribine-treated patients, the overall incidence of 
  infections was similar across treatment groups: infections 
or infestations were reported in 47.7% of the patients in 
the cladribine 3.5-mg/kg group, 48.9% in the cladribine 
5.25-mg/kg group, and 42.5% in the placebo group, with 
most of the events graded as mild or moderate by inves-
tigators (99.6% and 98.6%, respectively, vs 99.0%).26 
There were no cases of herpes zoster in the placebo group 
compared with 8 (1.9%) cases and 12 (2.6%) cases of her-
pes zoster in the 3.5 mg/kg group and 5.35 mg/kg group 
respectively. However, all cases were dermatomal and 
self-limiting and there have been no reports of disseminated 
herpes zoster.28 The occurrence of neoplasms (benign, 
malignant, or unspecified) was reported as an SAEs in 1.4% 
of patients in the cladribine 3.5-mg/kg group and in 0.9% 
of those in the cladribine 5.25-mg/kg group, as compared 
with no patients in the placebo group.28 On the basis of the 
small number of neoplasms, developed in different solid 
organs after relatively short intervals from treatment to 
diagnosis it is not possible to establish a risk due to the use of 
cladribine tablets. One patient treated with cladribine tablets 
had reactivation of latent tuberculosis and died. The use of 
cladribine may have contributed to this reactivation, and 
tuberculosis screening measures were immediately intro-
duced   subsequently in on-going trials.
Ongoing clinical trials
Following the completion of the CLARITY study, the 
96-week CLARITY EXTENSION study is currently ongoing 
and will provide data on the long-term safety and efficacy of 
extended treatment with cladribine tablets in patients who 
completed the CLARITY study. This study will primar-
ily provide further information on the longer-term safety 
and tolerability of cladribine tablets administered for an 
Table 2 CLARiTY: Clinical and imaging end points and relapses during the 96-week study28
Endpoint Cladribine 3.5 mg/kg Cladribine 5.25 mg/kg Placebo P value
Relapse
Annualized relapse rate over 
96 weeks
0.14 0.15 0.33 ,0.001a,b
Proportion of patients relapse 
free over 96 weeks
79.7% 78.9% 60.9% ,0.001a,b
Time to first relapse, months 13.4 13.3 4.6 ,0.001a,b
Disability
Risk of 3-month sustained disability  
progression on eDSS: Hazard 
ratio vs placebo, [95% Ci]
0.67 [0.49, 0.96] 0.69 [0.48, 0.93] 0.018a 
0.026a
Magnetic resonance imaging
Mean number of T1 Gd+ lesions 
per subject per scan over 96 weeks
0.12 0.11 0.91 ,0.001a,b
Relative reduction in mean number  
of T1 Gd+ lesions relative  
to placebo over 96 weeks
85.7% 87.9%
Mean number of active T2 lesions  
per subject per scan over 96 weeks
0.35 0.29 1.38 ,0.001a,b
Relative reduction in mean number  
of active T2 lesions relative  
to placebo over 96 weeks
73.4% 76.9%
Mean number of CU lesions per subject  
per scan over 96 weeks
0.39 0.33 1.65 ,0.001a,b
Relative reduction in mean number of active  
CU lesions relative to placebo over 96 weeks
74.4% 77.9%
Notes: a3.5 mg/kg dosage; b5.25 mg/kg dosage.
Abbreviations: CU, combined unique; eDSS, expanded disability status scale; Gd+, gadolinium-enhancing.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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additional third and fourth year in patients with RRMS. The 
extension study will also provide an opportunity to evalu-
ate the sustained effects of treatment after only four or six 
courses of cladribine tablets received in the prior 2 years of 
the CLARITY parent study. Patients originally randomized 
to placebo will receive cladribine tablets, whereas those 
originally randomized to cladribine will be rerandomized 
to either cladribine tablets or placebo. In addition to clinical 
endpoints, safety assessments will include hematological 
monitoring and liver function testing.31 Since many patients 
with MS are currently receiving DMD therapy but have sub-
optimal response, additional studies are needed to investigate 
the potential benefits and risks of adding a treatment such 
as cladribine tablets. This would also have the advantage 
of adding to our understanding of the additive efficacy of 
cladribine in terms of severity and frequency of relapse 
and improvements in MRI measures, relative to that obtained 
with established DMDs. It is hoped that this will be achieved 
from the ONWARD (Oral cladribine added oN to Rebif New 
Formulation in patients With Active Relapsing Disease) trial, 
comparing the addition of cladribine tablets or placebo to 
existing IFNβ therapy. The ONWARD trial is a 96-week, 
randomized, double blind, placebo-controlled, phase IIb trial 
in patients with active relapsing MS. This ongoing study will 
evaluate the safety and tolerability of oral cladribine tablets 
as an add-on therapy to IFNβ-1a.32 The study will recruit 260 
patients already receiving IFNβ (Rebif, Betaseron or Avonex) 
who have active relapsing MS, defined as $1 relapse in the 
preceding 48 weeks. Cladribine tablets will be administered 
in short courses, as in the CLARITY study: once-daily for 4–5 
consecutive days per month (28-day period). The study will 
evaluate as primary safety endpoints the proportion of patients 
developing grade 3 or 4 toxicity on selected hematology and 
liver function parameters, and incidence of infections. The 
primary efficacy endpoint is the mean change in the number 
of new T1 Gd-enhancing lesions per patient per scan from 
baseline to 96 weeks. Secondary endpoints include other MRI 
measures, relapse rate and disability progression.32
In order to support cladribine tablets as a first-line 
therapy another study will evaluate the efficacy and safety 
of   monotherapy with cladribine tablets versus placebo to 
prevent conversion to clinically definite MS in patients with 
a first clinical demyelinating event at high risk of developing 
MS. ORACLE (ORAl CLadribine in Early MS) is a 96-week, 
randomized, double-blind, placebo-controlled, international 
trial involving more than 600 patients considered at risk of 
developing MS due to a recently-experienced isolated demy-
elinating event and having MRI brain scans consistent with 
early signs of MS. Study participants will be randomized to 
receive one of two different dosage regimens of cladribine 
tablets or matching placebo tablets (1:1:1). The primary end-
point of the ORACLE MS trial is time to conversion to MS, 
according to the McDonald criteria. Other endpoints include 
time to conversion to clinically definite MS according to the 
Poser criteria (the main secondary endpoint), assessments of 
MRI brain scans, and disability progression.33
The importance of adherence
Since MS is a currently incurable, chronic disease, long-term 
DMD therapy is required, which requires commitment from 
patients to continue their treatment indefinitely. Adherence 
is a primary determinate of the effectiveness of any treatment 
and poor adherence attenuates optimum clinical benefit. 
Poor or nonadherence to treatment has been recognized as a 
major problem in the healthcare system, and has been widely 
reported in a variety of disease states for both parenteral and 
oral medications. Poor adherence to prescribed medication is 
associated with increased patient morbidity, poorer quality of 
life, and increased financial strain on healthcare institutions.34 
Maintaining adherence to DMDs is a daily challenge to those 
who manage and coordinate care for MS patients. Several 
reviews have estimated nonadherence rates in patients treated 
with DMDs, with results varying between 6% and 43%. 
There are several possible explanations for this trend. Firstly 
all treatment benefits cannot be felt immediately and inject-
able therapy (along with their associated side effects) may 
be prescribed when the patient feels well, so many patients 
are reluctant to experience the side effects for a benefit that 
is yet to be observed. Other factors can also contribute to 
nonadherence conduct. In one study the most common reason 
listed by participants for missing treatment, was that they 
simply forgot to administer it (58%). Others missed injections 
because they did not feel like taking the medication (22%) or 
were tired of taking injections (16%).35 Nonadherent behavior 
is closely linked to factors directly related to the performance 
of injection therapy, such as being tired of taking injections, 
skin reactions, pain at injection sites, injection-related anxiety, 
reduced manual dexterity or cognitive impairment.
Flu-like syndrome is a common complaint, reported as a 
side effect more often by patients treated with IFNβ therapy 
than with glatiramer acetate. Amongst these side effects 
the most uncomfortable one, according to patients, is the 
flu-like syndrome they experience especially at the onset of 
the treatment. Patients may feel that the treatment interferes 
with other important aspects of daily life and consequently 
perceive their therapy in a negative way.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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It has been widely reported that patients who have more 
positive feelings towards prescribed therapy adhere more 
closely to their therapeutic regimen. The development 
of drugs with easier administration, such as oral agents, 
would further promote adherence. Patients express greater 
satisfaction with the convenience of oral therapies, and oral 
medications are known to be preferred to injected therapies 
that have similar efficacy.36,37
Furthermore patients prefer less-frequent dosing of oral 
therapy to more-frequent dose regimens.38 The introduction 
of therapies for MS that are more acceptable to the patient 
could increase the number of patients with this chronic 
progressive disease being treated, reducing discomfort and 
inconvenience, making it easier for patients to adhere to their 
treatment regimen and thus improving efficacy.39 Therefore, 
improved adherence will result in better treatment outcomes, 
reducing disability, morbidity and the economic burden on 
the healthcare system.
Conclusions
The availability of cladribine tablets to treat MS in 
the near future could present several advantages. Firstly, the 
improvement of adherence to treatment and quality of life 
of patients with MS. Secondly, the mechanism of action of 
cladribine suggests its suitability for use as a monotherapy 
and as combination therapy, leading to increased efficacy 
with acceptable safety for those patients who do not respond 
adequately to single-agent therapies.
Adherence to prescribed treatment is essential for optimal 
long-term efficacy of pharmacotherapies for chronic condi-
tions such as MS.
Cladribine has a mechanism of action, pharmacokinetic 
profile and a lasting effect on lymphocyte populations that 
permits short-course dosing, requiring only 8–20 days of 
treatment each year. This short and intermittent dosing 
regimen is expected to have a positive impact on patients’ 
adherence to therapy and quality of life.
The CLARITY study is designed to assess the use of 
cladribine tablets as first-line therapy for MS. However, 
their mode of action also makes cladribine tablets a   potential 
candidate for use in combination with available DMDs. 
The use of drug combinations with synergistic mechanisms 
holds promise for enhanced therapeutic benefit and may 
allow avoidance of dose-limiting toxicity. Moreover, the 
short-course, intermittent dosing schedule of cladribine 
tablets is likely to be a convenient and acceptable regimen 
for use as an add-on therapy. As such, add-on treatment with 
cladribine tablets may be of benefit for patients experiencing 
breakthrough disease while receiving active treatment with 
an existing DMD. However, the potential for additional side 
effects and toxicity must be considered.
Safety is likely to become the most important factor in the 
future development of MS drugs. The safety of drug combi-
nations will be crucial to future therapeutic decision-making 
and more research is also needed to compare escalation and 
induction treatment strategies.
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